▶ 調査レポート

世界のニボルマブ注射市場予測(~2028年):100IU、50IU、その他

• 英文タイトル:Global Nivolumab Injection Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが調査・発行した産業分析レポートです。世界のニボルマブ注射市場予測(~2028年):100IU、50IU、その他 / Global Nivolumab Injection Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 / GIR-22E8906資料のイメージです。• レポートコード:GIR-22E8906
• 出版社/出版日:GlobalInfoResearch / 2022年5月
• レポート形態:英文、PDF、91ページ
• 納品方法:Eメール(2~3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
ニボルマブ注射市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のニボルマブ注射の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx%の成長率で成長すると予想されます。

ニボルマブ注射市場は種類と用途によって区分されます。2017年~2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・100IU、50IU、その他

用途別セグメントは次のように区分されます。
・切除不能黒色腫、転移性黒色腫、転移性扁平上皮NSCLC、古典的ホジキンリンパ腫、腎細胞癌、その他

世界のニボルマブ注射市場の主要な市場プレーヤーは以下のとおりです。
・AbbVie、Allergan、Ono Pharmaceutical、Sinopharm、Bristol-Myers Squibb

地域別セグメントは次の地域・国をカバーします。
・北米(米国、カナダ、メキシコ)
・ヨーロッパ(ドイツ、フランス、イギリス、ロシア、イタリア)
・アジア太平洋(日本、中国、韓国、インド、東南アジア、オーストラリア)
・南アメリカ(ブラジル、アルゼンチン、コロンビア)
・中東およびアフリカ(サウジアラビア、UAE、エジプト、南アフリカ)

本調査レポートの内容は計15章あります。
・第1章では、ニボルマブ注射製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なニボルマブ注射メーカーの企業概要、2019年~2022年までのニボルマブ注射の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なニボルマブ注射メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年~2028年までの地域別ニボルマブ注射の販売量、売上、成長性を示しています。
・第5、6章では、2017年~2028年までのニボルマブ注射の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年~2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年~2028年までの主要地域でのニボルマブ注射市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびニボルマブ注射の産業チェーンを掲載しています。
・第13、14、15章では、ニボルマブ注射の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):AbbVie、Allergan、Ono Pharmaceutical、Sinopharm、Bristol-Myers Squibb
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年:100IU、50IU、その他
・用途別分析2017年-2028年:切除不能黒色腫、転移性黒色腫、転移性扁平上皮NSCLC、古典的ホジキンリンパ腫、腎細胞癌、その他
・ニボルマブ注射の北米市場規模2017年-2028年:アメリカ、カナダ、メキシコ
・ニボルマブ注射のヨーロッパ市場規模2017年-2028年:ドイツ、イギリス、フランス、ロシア、イタリア
・ニボルマブ注射のアジア市場規模2017年-2028年:中国、日本、韓国、インド、東南アジア、オーストラリア
・ニボルマブ注射の南米市場規模2017年-2028年:ブラジル、アルゼンチン
・ニボルマブ注射の中東・アフリカ市場規模2017年-2028年:サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Nivolumab Injection market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Nivolumab Injection market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Unresectable Melanoma accounting for % of the Nivolumab Injection global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 100IU segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Nivolumab Injection include AbbVie, Allergan, Ono Pharmaceutical, Sinopharm, and Bristol-Myers Squibb, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Nivolumab Injection market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
100IU
50IU
Other
Market segment by Application can be divided into
Unresectable Melanoma
Metastatic Melanoma
Metastatic Squamous NSCLC
Classical Hodgkin Lymphoma
Renal Cell Carcinoma
Other
The key market players for global Nivolumab Injection market are listed below:
AbbVie
Allergan
Ono Pharmaceutical
Sinopharm
Bristol-Myers Squibb
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Nivolumab Injection product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Nivolumab Injection, with price, sales, revenue and global market share of Nivolumab Injection from 2019 to 2022.
Chapter 3, the Nivolumab Injection competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Nivolumab Injection breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Nivolumab Injection market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Nivolumab Injection.
Chapter 13, 14, and 15, to describe Nivolumab Injection sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Nivolumab Injection Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Nivolumab Injection Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 100IU
1.2.3 50IU
1.2.4 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Nivolumab Injection Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Unresectable Melanoma
1.3.3 Metastatic Melanoma
1.3.4 Metastatic Squamous NSCLC
1.3.5 Classical Hodgkin Lymphoma
1.3.6 Renal Cell Carcinoma
1.3.7 Other
1.4 Global Nivolumab Injection Market Size & Forecast
1.4.1 Global Nivolumab Injection Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Nivolumab Injection Sales in Volume (2017-2028)
1.4.3 Global Nivolumab Injection Price (2017-2028)
1.5 Global Nivolumab Injection Production Capacity Analysis
1.5.1 Global Nivolumab Injection Total Production Capacity (2017-2028)
1.5.2 Global Nivolumab Injection Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Nivolumab Injection Market Drivers
1.6.2 Nivolumab Injection Market Restraints
1.6.3 Nivolumab Injection Trends Analysis
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Nivolumab Injection Product and Services
2.1.4 AbbVie Nivolumab Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Allergan
2.2.1 Allergan Details
2.2.2 Allergan Major Business
2.2.3 Allergan Nivolumab Injection Product and Services
2.2.4 Allergan Nivolumab Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Ono Pharmaceutical
2.3.1 Ono Pharmaceutical Details
2.3.2 Ono Pharmaceutical Major Business
2.3.3 Ono Pharmaceutical Nivolumab Injection Product and Services
2.3.4 Ono Pharmaceutical Nivolumab Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Sinopharm
2.4.1 Sinopharm Details
2.4.2 Sinopharm Major Business
2.4.3 Sinopharm Nivolumab Injection Product and Services
2.4.4 Sinopharm Nivolumab Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business
2.5.3 Bristol-Myers Squibb Nivolumab Injection Product and Services
2.5.4 Bristol-Myers Squibb Nivolumab Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Nivolumab Injection Breakdown Data by Manufacturer
3.1 Global Nivolumab Injection Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Nivolumab Injection Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Nivolumab Injection
3.4 Market Concentration Rate
3.4.1 Top 3 Nivolumab Injection Manufacturer Market Share in 2021
3.4.2 Top 6 Nivolumab Injection Manufacturer Market Share in 2021
3.5 Global Nivolumab Injection Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Nivolumab Injection Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Nivolumab Injection Market Size by Region
4.1.1 Global Nivolumab Injection Sales in Volume by Region (2017-2028)
4.1.2 Global Nivolumab Injection Revenue by Region (2017-2028)
4.2 North America Nivolumab Injection Revenue (2017-2028)
4.3 Europe Nivolumab Injection Revenue (2017-2028)
4.4 Asia-Pacific Nivolumab Injection Revenue (2017-2028)
4.5 South America Nivolumab Injection Revenue (2017-2028)
4.6 Middle East and Africa Nivolumab Injection Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Nivolumab Injection Sales in Volume by Type (2017-2028)
5.2 Global Nivolumab Injection Revenue by Type (2017-2028)
5.3 Global Nivolumab Injection Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Nivolumab Injection Sales in Volume by Application (2017-2028)
6.2 Global Nivolumab Injection Revenue by Application (2017-2028)
6.3 Global Nivolumab Injection Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Nivolumab Injection Sales by Type (2017-2028)
7.2 North America Nivolumab Injection Sales by Application (2017-2028)
7.3 North America Nivolumab Injection Market Size by Country
7.3.1 North America Nivolumab Injection Sales in Volume by Country (2017-2028)
7.3.2 North America Nivolumab Injection Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Nivolumab Injection Sales by Type (2017-2028)
8.2 Europe Nivolumab Injection Sales by Application (2017-2028)
8.3 Europe Nivolumab Injection Market Size by Country
8.3.1 Europe Nivolumab Injection Sales in Volume by Country (2017-2028)
8.3.2 Europe Nivolumab Injection Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Nivolumab Injection Sales by Type (2017-2028)
9.2 Asia-Pacific Nivolumab Injection Sales by Application (2017-2028)
9.3 Asia-Pacific Nivolumab Injection Market Size by Region
9.3.1 Asia-Pacific Nivolumab Injection Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Nivolumab Injection Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Nivolumab Injection Sales by Type (2017-2028)
10.2 South America Nivolumab Injection Sales by Application (2017-2028)
10.3 South America Nivolumab Injection Market Size by Country
10.3.1 South America Nivolumab Injection Sales in Volume by Country (2017-2028)
10.3.2 South America Nivolumab Injection Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Nivolumab Injection Sales by Type (2017-2028)
11.2 Middle East & Africa Nivolumab Injection Sales by Application (2017-2028)
11.3 Middle East & Africa Nivolumab Injection Market Size by Country
11.3.1 Middle East & Africa Nivolumab Injection Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Nivolumab Injection Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Nivolumab Injection and Key Manufacturers
12.2 Manufacturing Costs Percentage of Nivolumab Injection
12.3 Nivolumab Injection Production Process
12.4 Nivolumab Injection Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Nivolumab Injection Typical Distributors
13.3 Nivolumab Injection Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer